CSG's Stark Divergence: Record Revenues, But Shareholders Staring at a 53% Rout

CSG shares collapse amid short seller allegations over artillery shell capacity, opaque contracts, and debt concerns, even as sales surge 71%.

The Czechoslovak Group is a study in contradictions. The Czech defence contractor closed Monday at €15.86 in Amsterdam, clinging just above its year low. That marks a collapse of more than 53% from January's peak. Over the past 30 days alone, the stock has shed 27.21% of its value—a far steeper decline than the broader Prague market, where the PX index dipped only 0.26% on the same Monday session. In local currency, CSG ended the day at 380 CZK, down 4.52%, while peer Colt CZ fell a comparatively modest 2.65%.

Yet behind the bleeding share price sits a business firing on most operational cylinders. Revenue surged 71.7% last year to €6.7 billion, with net profit hitting €872 million. The company now guides for fiscal 2025 sales between €7.4 billion and €7.6 billion, and an adjusted EBIT margin of 24% to 25%. The order book has swelled to €15 billion, anchored by a framework agreement with Poland's PGZ covering drone engines and rockets, and a $2.5 billion contract for air-defence systems in Southeast Asia.

The issue, investors increasingly suspect, is not the top line but the narrative underpinning the stock. Short seller Hunterbrook Media recently published a report challenging the group's transparency and, more pointedly, its actual production capacity for 155-millimetre artillery shells—a cornerstone of the company's growth story. Management has consistently cited an annual capacity of roughly 630,000 rounds, but Hunterbrook estimates that output from the central assembly line may have ranged between just 100,000 and 280,000 shells last year. If a meaningful portion of reported munitions revenue comes from re-selling rather than in-house manufacturing, the implied margins and scalability look less compelling. CSG has forcefully denied any misconduct and pointed to the rigorous due diligence of the IPO process, led by top-tier banks and law firms.

Other clouds have gathered. A non-formalised framework contract with Slovakia worth an eye-popping €58 billion is tied to the European SAFE programme, which provides cheap financing. That exemption expires in late May; unless Bratislava secures a partner state, funding costs could rise and future orders slip. Minority shareholder Petr Kratochvíl is reportedly demanding €1.4 billion for his stake and wields blocking rights over a key subsidiary. And a NATO procurement agency temporarily suspended a Spanish munitions factory owned by CSG over what the agency described as potentially sanctionable practices—though the company has pushed back.

Management insists that even a ceasefire in Ukraine, often cited as a risk to defence stocks, would only shift demand towards modernisation programmes rather than dry it up. But the market is voting with its feet. On the World Defense Show in Riyadh, CSG subsidiaries showcased Tatra trucks and artillery systems, yet the group's debt is projected to remain at roughly €4 billion through 2028, limiting financial flexibility.

All eyes are now on May 20, when the company publishes its first quarterly results since the Amsterdam listing. The report will reveal one-time costs tied to the IPO and, more crucially, whether the underlying margin can sustain the expense of being a listed entity. Nine analysts still rate the stock a buy, with an average price target of €35.40. But for that gap to close, the numbers on May 20 will need to do more than just appear strong—they will need to restore a trust that has been shattered in far less time than it took to build the business.